To investigate the mechanism of Yiwei Decoction in the treatment of premature ovarian insufficiency-related osteoporosis using transcriptomics, network pharmacology and molecular docking techniques

Abstract To investigate the molecular mechanism of Yiwei Decoction (YWD) in preventing Premature ovarian insufficiency (POI)-related osteoporosis from the hypothalamic perspective , and to screen for the key active and acting molecules in YWD. Cyclophosphamide was used to create the POI rat model. G...

Full description

Bibliographic Details
Main Authors: Weisen Fan, Yan Meng, Jing Zhang, Muzhen Li, Yingjie Zhang, Xintian Qu, Xin Xiu
Format: Article
Language:English
Published: Nature Portfolio 2023-11-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-45699-8
_version_ 1827770662282854400
author Weisen Fan
Yan Meng
Jing Zhang
Muzhen Li
Yingjie Zhang
Xintian Qu
Xin Xiu
author_facet Weisen Fan
Yan Meng
Jing Zhang
Muzhen Li
Yingjie Zhang
Xintian Qu
Xin Xiu
author_sort Weisen Fan
collection DOAJ
description Abstract To investigate the molecular mechanism of Yiwei Decoction (YWD) in preventing Premature ovarian insufficiency (POI)-related osteoporosis from the hypothalamic perspective , and to screen for the key active and acting molecules in YWD. Cyclophosphamide was used to create the POI rat model. Groups A, B, and C were established. The Model + YWD group was group A, the model control group was group B, and the normal control group was group C. ELISA was used to determine serum GnRH and FSH levels after gavage. The transcription levels of mRNAs in each group's hypothalamus tissues were examined using RNA-seq sequencing technology. The GSEA method was used to enrich pathways based on the gene expression levels of each group. The TCM–active ingredient–target–disease network map was created using differentially expressed mRNAs (DEmRNAs) and network pharmacology. The molecular docking method was employed to investigate the affinity of the active ingredient with key targets. GnRH and FSH levels in POI rats' serum were reduced by YWD. Between groups A and B, there were 638 DEmRNAs (P < 0.05) and 55 high-significance DEmRNAs (P-adjust < 0.01). The MAPK, Hedgehog, Calcium, and B cell receptor pathways are primarily enriched in DEmRNAs from Group A and Group B. The GSEA pathway enrichment analysis indicates that YWD may regulate Long-term potentiation, Amphetamine addiction, and the Renin-angiotensin system and play a role in preventing osteoporosis. The Chinese herbal medicine (CHM)—Active ingredient-Target-disease network map includes 137 targets, 4 CHMs, and 22 active ingredients. The result of docking indicated that Stigmasterol, interacts well with the core proteins ALB, VCL and KAT5. Following the screening, we identified the targets, active components, and key pathways associated with YWD osteoporosis prevention. Most of these key targets and pathways are associated with osteoporosis, but further experimental validation is required.
first_indexed 2024-03-11T12:42:46Z
format Article
id doaj.art-76a3007131af42079b8915df78e49905
institution Directory Open Access Journal
issn 2045-2322
language English
last_indexed 2024-03-11T12:42:46Z
publishDate 2023-11-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj.art-76a3007131af42079b8915df78e499052023-11-05T12:12:23ZengNature PortfolioScientific Reports2045-23222023-11-0113111410.1038/s41598-023-45699-8To investigate the mechanism of Yiwei Decoction in the treatment of premature ovarian insufficiency-related osteoporosis using transcriptomics, network pharmacology and molecular docking techniquesWeisen Fan0Yan Meng1Jing Zhang2Muzhen Li3Yingjie Zhang4Xintian Qu5Xin Xiu6First Clinical College of Medicine, Shandong University of Traditional Chinese MedicineSchool of Health, Shandong University of Traditional Chinese MedicineSchool of Health, Shandong University of Traditional Chinese MedicineCollege of Acupuncture and Massage, Shandong University of Traditional Chinese MedicineFirst Clinical College of Medicine, Shandong University of Traditional Chinese MedicineFirst Clinical College of Medicine, Shandong University of Traditional Chinese MedicineFirst Clinical College of Medicine, Shandong University of Traditional Chinese MedicineAbstract To investigate the molecular mechanism of Yiwei Decoction (YWD) in preventing Premature ovarian insufficiency (POI)-related osteoporosis from the hypothalamic perspective , and to screen for the key active and acting molecules in YWD. Cyclophosphamide was used to create the POI rat model. Groups A, B, and C were established. The Model + YWD group was group A, the model control group was group B, and the normal control group was group C. ELISA was used to determine serum GnRH and FSH levels after gavage. The transcription levels of mRNAs in each group's hypothalamus tissues were examined using RNA-seq sequencing technology. The GSEA method was used to enrich pathways based on the gene expression levels of each group. The TCM–active ingredient–target–disease network map was created using differentially expressed mRNAs (DEmRNAs) and network pharmacology. The molecular docking method was employed to investigate the affinity of the active ingredient with key targets. GnRH and FSH levels in POI rats' serum were reduced by YWD. Between groups A and B, there were 638 DEmRNAs (P < 0.05) and 55 high-significance DEmRNAs (P-adjust < 0.01). The MAPK, Hedgehog, Calcium, and B cell receptor pathways are primarily enriched in DEmRNAs from Group A and Group B. The GSEA pathway enrichment analysis indicates that YWD may regulate Long-term potentiation, Amphetamine addiction, and the Renin-angiotensin system and play a role in preventing osteoporosis. The Chinese herbal medicine (CHM)—Active ingredient-Target-disease network map includes 137 targets, 4 CHMs, and 22 active ingredients. The result of docking indicated that Stigmasterol, interacts well with the core proteins ALB, VCL and KAT5. Following the screening, we identified the targets, active components, and key pathways associated with YWD osteoporosis prevention. Most of these key targets and pathways are associated with osteoporosis, but further experimental validation is required.https://doi.org/10.1038/s41598-023-45699-8
spellingShingle Weisen Fan
Yan Meng
Jing Zhang
Muzhen Li
Yingjie Zhang
Xintian Qu
Xin Xiu
To investigate the mechanism of Yiwei Decoction in the treatment of premature ovarian insufficiency-related osteoporosis using transcriptomics, network pharmacology and molecular docking techniques
Scientific Reports
title To investigate the mechanism of Yiwei Decoction in the treatment of premature ovarian insufficiency-related osteoporosis using transcriptomics, network pharmacology and molecular docking techniques
title_full To investigate the mechanism of Yiwei Decoction in the treatment of premature ovarian insufficiency-related osteoporosis using transcriptomics, network pharmacology and molecular docking techniques
title_fullStr To investigate the mechanism of Yiwei Decoction in the treatment of premature ovarian insufficiency-related osteoporosis using transcriptomics, network pharmacology and molecular docking techniques
title_full_unstemmed To investigate the mechanism of Yiwei Decoction in the treatment of premature ovarian insufficiency-related osteoporosis using transcriptomics, network pharmacology and molecular docking techniques
title_short To investigate the mechanism of Yiwei Decoction in the treatment of premature ovarian insufficiency-related osteoporosis using transcriptomics, network pharmacology and molecular docking techniques
title_sort to investigate the mechanism of yiwei decoction in the treatment of premature ovarian insufficiency related osteoporosis using transcriptomics network pharmacology and molecular docking techniques
url https://doi.org/10.1038/s41598-023-45699-8
work_keys_str_mv AT weisenfan toinvestigatethemechanismofyiweidecoctioninthetreatmentofprematureovarianinsufficiencyrelatedosteoporosisusingtranscriptomicsnetworkpharmacologyandmoleculardockingtechniques
AT yanmeng toinvestigatethemechanismofyiweidecoctioninthetreatmentofprematureovarianinsufficiencyrelatedosteoporosisusingtranscriptomicsnetworkpharmacologyandmoleculardockingtechniques
AT jingzhang toinvestigatethemechanismofyiweidecoctioninthetreatmentofprematureovarianinsufficiencyrelatedosteoporosisusingtranscriptomicsnetworkpharmacologyandmoleculardockingtechniques
AT muzhenli toinvestigatethemechanismofyiweidecoctioninthetreatmentofprematureovarianinsufficiencyrelatedosteoporosisusingtranscriptomicsnetworkpharmacologyandmoleculardockingtechniques
AT yingjiezhang toinvestigatethemechanismofyiweidecoctioninthetreatmentofprematureovarianinsufficiencyrelatedosteoporosisusingtranscriptomicsnetworkpharmacologyandmoleculardockingtechniques
AT xintianqu toinvestigatethemechanismofyiweidecoctioninthetreatmentofprematureovarianinsufficiencyrelatedosteoporosisusingtranscriptomicsnetworkpharmacologyandmoleculardockingtechniques
AT xinxiu toinvestigatethemechanismofyiweidecoctioninthetreatmentofprematureovarianinsufficiencyrelatedosteoporosisusingtranscriptomicsnetworkpharmacologyandmoleculardockingtechniques